XTL Biopharmaceuticals Ltd. Sponsored ADR's market cap is currently ―. The company's EPS TTM is $-0.412; its P/E ratio is -5.92; XTL Biopharmaceuticals Ltd. Sponsored ADR is scheduled to report earnings on December 5, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	-	$ -896.00K	$ -274.00K	$ -249.00K	$ -286.00K
EBITDA	-	$ -896.00K	$ -274.00K	$ -249.00K	$ -286.00K
Net Income Common Stockholders	-	$ -821.00K	$ -285.00K	$ 506.00K	$ 2.10M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 2.09M	$ 4.39M	$ 5.16M	$ 2.79M	$ 2.97M
Total Assets	$ 4.19M	$ 4.90M	$ 5.76M	$ 6.62M	$ 6.62M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -2.09M	$ -4.39M	$ -5.16M	$ -2.79M	$ -2.97M
Total Liabilities	$ 14.33M	$ 153.00K	$ 194.00K	$ 777.00K	$ 6.62M
Stockholders Equity	$ -10.14M	$ 4.74M	$ 5.56M	$ 5.84M	$ -8.81M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

XTL Biopharmaceuticals Ltd. Sponsored ADR Earnings and Revenue History

Income Statement >

XTL Biopharmaceuticals Ltd. Sponsored ADR Debt to Assets

Balance Sheet >

XTL Biopharmaceuticals Ltd. Sponsored ADR Cash Flow

Cash Flow >

XTL Biopharmaceuticals Ltd. Sponsored ADR Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing